Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs. Lyvgen’s most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409, a mAb agonist for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGFβ1/2/3, and anti-PD-1 blocking antibody LVGN3616. Lyvgen has initiated Phase I clinical trial of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA. Lyvgen plans to start Phase I testing of LVGN6051 in China, LVGN7409 and LVGN1673 globally. Lyvgen employs over 35 scientists with global pharmaceutical research and development experiences at its research sites in China and the USA.
Company Details
- Employees
- 18
- Founded
- -
- Address
- 1043 Halei Road, Suite 601b,building 8,china
- Industry
- Biotechnology
- Website
- http://www.lyvgen.com
- HQ
- shanghai, Shanghai
Lyvgen Biopharma Questions
Lyvgen Biopharma's website is http://www.lyvgen.com
Lyvgen Biopharma's LinkedIn profile is https://cn.linkedin.com/company/lyvgen-biopharma
Lyvgen Biopharma has
18 employees.
View email and phone details for 18
employees at Lyvgen Biopharma.
Lyvgen Biopharma's industry is
Biotechnology
Lyvgen Biopharma's top competitors are
Institut Pasteur Of Shanghai,
Io Biotech,
Hope Medicine Inc,
益方生物 Inventisbio,
Daiichi Sankyo,
Glyconex Inc.,
Hyatt Pharmacy,
Rx Biosciences Llc,
Eikon Therapeutics,
Hygiea.
Lyvgen Biopharma's categories are Biotechnology
Lyvgen Biopharma's founding year is 2016
